Research on the Heterogeneity of Taiwanese Breast Cancer Patients by Next Generation Sequencing (NGS) Tools

Recruiting

• Conditions: Next Generation Sequencing (NGS); Breast Cancer
• Interventions: Procedure: Diagnostic stage or the Clinical outcome

• Registration Number: NCT04626440
• Lead Sponsor: vghtpe user

Brief Summary

The objectives of this study are:

1. To determine the difference in genetic profiling of subjects with breast cancer recurrence

2. To determine the comprehensive genetic profiling of subjects with late stage breast cancer

3. To determine the potential biomarkers for early detection and prognosis for breast cancer

4. To determine the genetic profiling of immune system in different subtypes of breast cancer

By integrating and analyzing the data generated using the methods of NGS, these information can be used for:

1. Understanding the genetic profiling of different subtypes of breast cancer in Taiwan

2. Assessing the efficacy of different treatments in breast cancer subjects

3. Defining the molecular risk factors and predicting the potential risk of breast cancer recurrence

4. Assessing the immune repertoire and the potential effects of immunotherapy in breast cancer subjects

5. Developing new strategies in treating patients with triple negative or late stage of breast cancer

Detailed Description

Not available

Study Timeline

• Study Start: 2018-11-22
• Status Verified: 2020-11
• Study First Submitted: 2020-11-02
• Study First Submitted QC: 2020-11-06
• Last Update Submitted: 2020-11-06
• Study First Posted: 2020-11-12
• Last Update Posted: 2020-11-12
• Primary Completion: 2026-08-31
• Study Completion: 2026-08-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 1875

Inclusion Criteria

• Female subjects aged over 20 years old

• Subject with confirmed diagnosis of primary invasive breast cancer and is planning to receive treatments for breast cancer. However, subjects with breast cancer recurrence at screening will be enrolled if meet both the following conditions:

  1. Subjects had received surgery for primary breast cancer within 3 years prior to screening [i.e. recurrence within 3 years after surgery (mastectomy or BCS)];
  2. Subjects diagnosed with stage IV breast cancer beyond 3 years after surgery (mastectomy or BCS) or who had received or are currently receiving treatments for breast cancer. And subjects with primary tumor FFPE tissues available and pass the RNA quality check.

• Eastern Cooperative Oncology Group (ECOG) Performance score ≤ 3

• Life expectancy ≥ 3 months

• Subject agrees to provide the written informed consent. If a subject has breast cancer recurrence within 3 years prior to screening, she will be eligible if she agrees to provide the paired FFPE tissues (primary and recurrent tumors)

Exclusion Criteria

• Subjects will be excluded if they had primary cancer other than breast cancer within 5 years prior to screening

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Group 2	Diagnostic stage or the Clinical outcome	subjects who are planning to receive neoadjuvant therapy as the first-line treatment for BC and followed by surgery
Group 1	Diagnostic stage or the Clinical outcome	Group 1 \[(A) subjects who are planning to receive surgery (mastectomy or BCS) as the first-line treatment for BC and followed by adjuvant therapy, or (B) subjects with BC recurrence at screening, who had received surgery for primary BC within 3 years prior to screening, and with primary tumor FFPE tissues available\]
Group 3	Diagnostic stage or the Clinical outcome	Group 3-1 (subjects diagnosed with de novo and treatment naïve stage IV BC); or Group 3-2 \[(A) stage IV subjects with BC recurrence beyond 3 years after surgery (mastectomy or BCS) or stage IV subjects who had received or are currently receiving treatments for BC\].

Primary Outcome Measures

Name	Time	Method
The rate of genomic alteration	Aug.2026	Discovery of comprehensive genetic profiles including copy number variation and single nucleotide polymorphism in group 1, 2 and 3 subjects.; Discovery of genetic mutations of T cell receptor
Clinical outcome	Aug.2026	Breast cancer recurrence, overall survival and recurrence-free survival

Trial Locations

Locations (1)

Taipei Veterans General Hospital; 🇨🇳 Taipei, Taiwan